FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:185-187 July 8, 2004 Number 2 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Despite advances in the management of congestive heart failure (CHF), most patients with advanced forms die within a year after receiving the diagnosis. Half of all deaths from CHF are caused by ventricular tachycardia, and about 80 percent of patients with symptomatic systolic dysfunction have ventricular tachycardia. Ischemia and myocardial scars are major determinants of the risk of ventricular tachycardia, along with some CHF therapies themselves — for example, inotropic agents such as milrinone and dobutamine. Other available medications include beta-blockers, agents that block the renin–angiotensin–aldosterone pathway, vasodilators, diuretics, and natriuretics. A new study by Wehrens et al.¹ points to . . . [Full Text of this Article]

Source Information

From the Molecular Cardiology Laboratory and Congestive Heart Failure Center, Greenberg Cardiology Division, Department of Medicine, Weill Medical College of Cornell University, New York.

This article has been cited by other articles:

• Wu, J. C., Bengel, F. M., Gambhir, S. S. (2007). Cardiovascular Molecular Imaging. Radiology 244: 337-355 [Abstract] [Full Text]